Jazz Pharmaceuticals’ (JAZZ) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research report report published on Thursday morning, Benzinga reports. Needham & Company LLC currently has a $222.00 price target on the specialty pharmaceutical company’s stock.

Several other analysts have also recently commented on the stock. Piper Sandler raised their price target on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an overweight rating in a report on Wednesday, March 20th. Cantor Fitzgerald reaffirmed an overweight rating and set a $180.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, April 10th. UBS Group cut their price objective on shares of Jazz Pharmaceuticals from $135.00 to $131.00 and set a neutral rating on the stock in a research report on Friday, March 1st. Barclays cut their price objective on shares of Jazz Pharmaceuticals from $235.00 to $230.00 and set an overweight rating on the stock in a research report on Friday, March 1st. Finally, Stifel Nicolaus raised their price objective on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a buy rating in a research report on Friday, March 15th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of Moderate Buy and a consensus price target of $192.75.

Jazz Pharmaceuticals Stock Up 0.7 %

Shares of JAZZ stock traded up $0.72 during trading on Thursday, hitting $110.01. 693,769 shares of the company were exchanged, compared to its average volume of 597,957. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.85 and a current ratio of 2.27. The firm has a market capitalization of $6.94 billion, a price-to-earnings ratio of 22.68, a P/E/G ratio of 1.52 and a beta of 0.63. The business’s 50-day simple moving average is $116.44 and its 200 day simple moving average is $121.02. Jazz Pharmaceuticals has a twelve month low of $103.01 and a twelve month high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing the consensus estimate of $4.44 by ($0.04). The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1.01 billion. Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. As a group, analysts forecast that Jazz Pharmaceuticals will post 16.24 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the transaction, the chief accounting officer now owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the transaction, the chief accounting officer now owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Philip L. Johnson bought 12,000 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were bought at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the transaction, the chief financial officer now directly owns 27,932 shares of the company’s stock, valued at approximately $3,342,063.80. The disclosure for this purchase can be found here. 4.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Rise Advisors LLC boosted its stake in Jazz Pharmaceuticals by 2,255.6% during the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock worth $26,000 after buying an additional 203 shares in the last quarter. Cape Investment Advisory Inc. boosted its stake in Jazz Pharmaceuticals by 14,600.0% during the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock worth $36,000 after buying an additional 292 shares in the last quarter. Covestor Ltd boosted its stake in Jazz Pharmaceuticals by 676.5% during the third quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company’s stock worth $51,000 after buying an additional 345 shares in the last quarter. Assetmark Inc. boosted its stake in Jazz Pharmaceuticals by 37.1% during the fourth quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 119 shares in the last quarter. Finally, Spire Wealth Management boosted its stake in shares of Jazz Pharmaceuticals by 128.6% in the 3rd quarter. Spire Wealth Management now owns 423 shares of the specialty pharmaceutical company’s stock valued at $55,000 after purchasing an additional 238 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.